# Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients

> **NCT01852045** · PHASE3 · COMPLETED · sponsor: **Allergan** · enrollment: 114 (actual)

## Conditions studied

- Urinary Incontinence

## Interventions

- **BIOLOGICAL:** OnabotulinumtoxinA

## Key facts

- **NCT ID:** NCT01852045
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07-02
- **Primary completion:** 2018-10-11
- **Final completion:** 2018-10-11
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2019-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01852045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01852045, "Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01852045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*